Manager TitleAgeSince
Chief Operating Officer - -
Corporate Officer/Principal - -
Comptroller/Controller/Auditor - -
Date Insider Type Main position Quantity % Market Cap. Importance
06/06/23 Other

Chief Executive Officer

61,085 0.2341%
28/12/22
Deerfield Management Co. LP
SellCompany 336,235 1.2945%
22/12/22
Deerfield Management Co. LP
SellCompany 73,384 0.2825%
Change 5-day change 1-year change 3-year change Capi.($)
-3.08%+869.23% - - 3.29M
+0.19%-3.96%+54.92%+69.15% 65.42B
-0.14%-3.20%+7.62%+89.74% 58.91B
+0.06%+0.15%+25.94%+87.89% 55.24B
-0.97%-3.91%+12.98%+113.88% 45.66B
-2.83%-7.58%+15.21%+22.34% 41.29B
+3.61%+2.63%+21.96%+46.39% 36.82B
-0.24%-9.59%+126.05%+647.44% 34.48B
+0.03%-0.93%+76.71%+57.74% 32.5B
+20.58%+22.35%-29.03%+482.03% 31.69B
Average +1.72%-0.39%+34.71%+179.62% 45B
Weighted average by Cap. +1.55%-0.98%+33.39%+154.16%
Logo Oncorus, Inc.
Oncorus, Inc. is a preclinical-stage biopharmaceutical company focused on the intravenous administration of self-amplifying RNA to transform outcomes for cancer patients. The Company's two product candidates from its self-amplifying RNA platform are ONCR-021 and ONCR-788. ONCR-021, a lead product candidate that is an IV administered viral RNA encoding an optimized genome of Coxsackievirus 21A (CVA21), is encapsulated within a lipid nanoparticle (LNP). The Company intends to develop ONCR-021 for non-small cell lung cancer, renal cell carcinoma, melanoma, anaplastic thyroid cancer, and hepatocellular carcinoma. The Company is also developing ONCR-788, which encodes for a modified version of the Seneca Valley Virus (SVV). The Company designed its HSV platform, including product candidate ONCR-719, to overcome the limitations in potency and in the ability to stimulate anti-tumor immunity that have both been encountered by previous viral immunotherapies and other immuno-oncology therapies.
Employees
64
  1. Stock Market
  2. Stocks
  3. ONCR Stock